IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint

The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs

NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration